09:53 AM EDT, 05/21/2024 (MT Newswires) -- Guardant Health ( GH ) said Tuesday that its Guardant360 CDx blood-based test for comprehensive genomic profiling of solid cancers has received certification under the European Union's In Vitro Diagnostic Regulation.

The test is certified as a companion diagnostic to identify non-small cell lung cancer patients who may benefit from treatment with osimertinib, amivantamab or sotorasib, and advanced breast cancer patients with ESR1 mutations who may benefit from elacestrant treatment, the company said.

With the test, clinicians can use comprehensive genomic profiling for the identification of somatic mutations in solid tumors from a blood draw to inform treatment decisions for their patients with advanced cancer, according to Guardant Health ( GH ).

Price: 24.60, Change: -0.17, Percent Change: -0.69